Approval of Ogivri

PDA J Pharm Sci Technol. 2018 Jan-Feb;72(1):1. doi: 10.5731/pdajpst.2018.001105.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use*
  • Biosimilar Pharmaceuticals / therapeutic use*
  • Drug Approval
  • Humans
  • India
  • Trastuzumab / therapeutic use*
  • United States

Substances

  • Antineoplastic Agents, Immunological
  • Biosimilar Pharmaceuticals
  • Ogivri
  • Trastuzumab